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1. Introduction
  Hepatocellular carcinoma (HCC) or liver cancer is the 
sixth most common cancer and the third leading cause of 
cancer mortality in the world[1]. The burden of cancer is 
increasing in economically developing countries as a result 
of population aging and growth as well as, increasingly, an 
adoption of cancer-associated lifestyle choices including 
smoking, physical inactivity, and “westernized” diets. 
Liver cancer in men/women is the fifth/seventh most 
frequently diagnosed cancer worldwide but the second/ 
sixth most frequent cause of cancer death.  An estimated 
748 300 new liver cancer cases and 695 900 cancer deaths 
occurred worldwide in 2008[2]. Hepatitis viral infection, 
food additives, alcohol, fungal toxins (aflatoxins), toxic 
industrial chemicals, air and water pollutants are the 
major risk factors of liver cancer[3]. Human liver is the 
major site in the body that metabolizes ingested material. 
It has pore to carcinogenic insult. Moreover, due to the 
high tolerance of liver, HCC is seldom detected at the early 
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stage and once detected treatment faces a poor prognosis 
in most cases[4]. N-nitrosodiethylamine (NDEA) is a 
potent hepatocarcinogenic nitrosamine present in tobacco 
smoke, water, cheddar cheese, cured and fried meals, 
occupational settings, cosmetics, agricultural chemicals and 
pharmaceutical agents[5].
  NDEA is widely accepted for induction of preneoplastic 
lesions and hepatic tumors in rats and it is initiated by 
perturbations of nuclear enzymes involved in DNA repair 
or replication[6]. Investigations have provided evidence that 
NDEA causes a wide range of tumors in all animal species 
and such compounds are hazardous to human health[7]. 
NDEA-induced lesions as well as tumors in rodents show 
marked biochemical, histological and molecular similarity to 
the progression of HCC in humans[8]. Many pharmaceutical 
agents have been discovered by screening natural products 
from plants, animals, marine organisms and microorganisms. 
Vincristine, vinblastine, irinotecan, etoposide and 
paclitaxel are examples of plant-derived compounds that 
are being employed in cancer treatment as well as several 
chemicals are also known to possess chemopreventive 
properties against a broad spectrum of cancer[9]. Recently, 
identification of bioactive ingredients from medicinal plants 
to inhibit tumorigenesis in a variety of animal models of 
carcinogenesis, involving organ sites, such as the skin, 
lungs, oral cavity, esophagus, stomach, liver, pancreas, 
small intestine, colon, and prostate is gaining considerable 
attention[10]. Moreover, in recent years, naturally occurring 
plant products have getting increased attention for the 
intervention of malignant invasive progression in the late 
stage of neoplastic diseases[11].
  Fumaria indica (F. indica) pugsely (Syn: Fumaria 
parviflora, Fumariaceae) is a small, scandent, branched 
annual herb growing wild in plains and lower hills. It 
has long been used as a household remedy and forms a 
constituent of many common Ayurvedic, Unani medicinal 
preparations and polyherbal liver formulation. The plant 
considered to be diuretic, diaphoretic, anthelmintic, laxative 
and used to purify blood and in obstruction of liver[12]. 
Pharmacological studies show that F. indica is a smooth 
muscles relaxant and possess antipyretic[13], analgesic, anti-
inflammatory[14], antidiarrhoeal[15], and hepatoprotective 
properties[16-19]. Phytochemical investigation revealed 
the presence of alkaloids viz. protopine[20], parfumine, 
fumari l ine,  fumaranine,  fumari t ine,  cryptopine, 
paprafumicin, paprarine, papraline, reddeanine[21], 
narlumicine, fumarophycine, steroids viz. 毬-sitosterol, 
stigmasterol, campesterol, organic acid viz. caffeic acid 
and fumaric acid[22]. Traditionally and scientifically proved 
reports suggested that F. indica is a successful and safe 
hepatoprotective agent and acts in a manner similar to that 
of silymarin and it is a more effective inducer of Phase 
II enzymes indicating its anticarcinogenic properties. 
Therefore, present study was designed to evaluate the 
chemopreventive potential of F. indica extract (FIE) against 
experimentally induced hepatocarcinogenesis in rats by 
assessing nodule incidence and tumor marker enzymes.
2.Materials and methods
2.1. Chemicals and their sources
  All the chemicals used were of analytical grade and 
procured from Sigma chemicals Co., USA and Qualigens fine 
chemicals, Mumbai, India.
2.2. Plant extraction and standardization
  The fresh plant of F. indica was collected in the botanical 
garden of National Botanical Research Institute, India 
in January 2010. The plant material was identified and 
authenticated and the voucher specimen number (NAB 
180023) was deposited in the departmental herbarium. The 
air dried powdered material (1 000 g) was extracted with 
petroleum ether thrice to remove fatty material and further 
marc was exhaustively extracted thrice with 50% aqueous 
ethanol by cold percolation method at room temperature. 
The extract was separated by filteration, concentrated at
(40±1) 曟 on rotavapour (Buchi, USA) to yield 9.85% (w/w)
of FIE. Preliminary qualitative phytochemical screening of 
FIE has given the positive testes for alkaloids, glycosides, 
flavonoids, tannins, saponins, steroids and triterpenoids. 
 
2.3.  Animals
  Wistar albino rats (150-170 g) and Swiss albino mice (25-30 g)
were procured from the National Laboratory Animal Centre, 
Central Drug Research Institute, Lucknow, India. The 
animals were housed separately in polypropylene cage at 
temperature of (22±2) 曟 and 50%-60% relative humidity, 
with a 12 h light/dark cycle respectively, for one week 
before and during the experiment. Animals were allowed to 
access standard rodent pellet diet (Dayal animal feed, India) 
and drinking water. Food was withdrawn 18-24 h before 
the experiment though water was allowed ad libitum and 
allocated to different experimental groups. All studies were 
performed according to the guidelines for the care and use 
of laboratory animals, as adopted and promulgated by the 
Institutional Animal Care Committee, CPCSEA, India (Reg. 
No. 1213/ac/2008/CPCSEA/IU).
 
2.4. Toxicity studies
  Acute toxicity study was performed for FIE according to 
the OECD guideline for acute toxic classic method[23]. Three 
female albino mice were used for each step in this study. 
The animals were kept fasting for overnight only on water, 
after which the extracts were administered orally at the 
single dose of 300 mg/kg and closely observed for the initial 
4 h after the administrations, and then once daily for 14 d. 
If mortality occurred in two out of three animals, then this 
dose was assigned as toxic dose. If the mortality occurred 
in one animal, then this same dose was repeated to confirm 
the toxic dose. If mortality did not occur, the procedure was 
repeated for further higher dose, i.e., 2 000 mg/kg. One-
tenth and one-fifth of the maximum tolerated dose of the 
extract tested for acute toxicity were selected for evaluation 
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of chemopreventive effect of FIE, i.e., 200 and 400 mg/kg.
 
2.5. Experimental design and induction of HCC
  The experimental animals were divided into six groups, 
each group comprising of six animals (n=6) for a study 
period of 20 weeks. Group 栺 served as normal control 
and treated with 0.9% normal saline throughout the study. 
HCC was induced in groups 栻, 栿, 桇 and 桋 with single 
intraperitoneal injection of NDEA in normal saline at a dose 
of 200 mg/kg body weight followed by weekly subcutaneous 
injections of CCl4 (3 mL/kg/week) for 6 weeks, as the promoter 
of carcinogenic effect[24]. After administration of NDEA, test 
groups 栿 and 桇 were administered orally 200 and 400 mg/kg 
FIE, respectively, in the form of aqueous suspension daily once 
a day throughout the study. Group 桋 received silymarin, the 
known hepatoprotective and anti-hepatocellular carcinoma
compound at a dose of 200 mg/kg[4,7]. The dose of FIE
(400 mg/kg alone) was administered orally to rats of group 
桍. The experiment was terminated at the end of 20 weeks 
of experimental period, the body weight of each rat was 
taken before sacrifice. The overnight fasted animals were 
anaesthetized and sacrificed 48 h after the last dose of the 
drug. Blood was collected by retro-orbital plexus followed 
by heart puncture and allowed to clot before centrifugation 
at 2 500 g for 15 min at 4 曟 to separate serum. The liver 
tissue was washed twice with ice cold saline, blotted, dried, 
observed for the presence of nodules and then weighed. The 
relative liver weight was calculated as the percentage ratio 
of liver weight to the body weight. A small portion of the 
tissue was fixed in formalin for histological examination. 
 
2.6. Assessment of liver injury markers and liver tumor 
markers
  The activities of biochemical parameters like aspartate 
transaminase (AST) and alanine transaminase (ALT) were 
estimated by the method of Reitman and Frankel[25] while 
alkaline phosphatase (ALP) and 毭-glutamyl transferase (毭 
-GT) were estimated by methods of King[26] and Szasz’s[27], 
respectively. Total bilirubin level (TBL) was determined by 
modified dimethyl sulfoxide (DMSO) method[28] on the basis 
of sulfanilic acid reaction with sodium nitrite to produce 
deoxidized sulfanilic acid. Quantitative estimation of tumor 
markers-毩-feto protein (AFP) and carcinoembryonic 
antigen (CEA) was based on solid phase enzyme linked 
immunosorbent assay using the UBI MAGIWELL (USA) 
enzyme immunoassay kit[29-30].
 
2.7. Histopathological assessment
  For histologic studies, the liver sections were made 
immediately from the liver of different groups of rats, fixed 
in 10% formalin, dehydrated in gradual ethanol (50%-100%), 
cleared in xylene, and embedded in paraffin wax. Sections 
were cut at 4 毺m thick (Automatic tissue processor, 
Lipshaw) in a rotary microtone and the pathological 
changes were observed microscopically after staining with 
hematoxylin and eosin (H&E).
 
2.8. Statistical analysis
  The data were represented as mean ± SEM. for six rats. 
Analysis of variance (ANOVA) test was followed by individual 
comparison by Newman-Keuls test using Prism Pad software 
(Version 3.0) for the determination of level of signifcance. 
The value of P<0.05 was considered statistically signifcant.
 
3. Results
3.1. Effect of FIE on body weight, liver weight and relative 
liver weight
 
  Table 1 shows the body weight (initial and final) and liver 
weights of control and experimental groups of animals. The 
final body weight of normal group 栺 rats showed (243.0±7.4)  g
which was significantly decreased to (P<0.001) (172.0±8.6) g 
comparatively in group 栻 rats following NDEA treatment. In 
FIE-treated group 栿 (200 mg/kg) and 桇 (400 mg/kg) rats, the 
final body weights became significantly increased (P<0.01) 
(212.0±9.8) and (P<0.001) (238.0±9.5) g when compared to the 
NDEA group 栻, respectively. Moreover, NDEA treatment 
significantly increased the relative liver weight to (P<0.001) 
(5.71±0.52)/100 g body weight when compared to the 
control [group栺, (2.93 ± 0.38)/100 g body weight]. However, 
administration of 200 and 400 mg/kg FIE significantly 
reduced (P<0.01 and P<0.001) the relative liver weight to 
(3.78 ± 0.47) and (3.15 ± 0.43)/100 g body weight, respectively, 
compared to (5.71 ± 0.52)/100 g in NDEA treatment. FIE 
Table 1
Effect of FIE on body weight, liver weight and relative liver weight of control and NDEA induced HCC in rats.
Groups Treatment Initial body weight 
(g)
Final body weight
 (g)
Liver weight 
(g)
Relative liver wt.
 (liver weight/100 g b.w.)
栺 Control 157.0 ± 6.3 243.0 ± 7.4 7.13 ± 0.41 2.93 ± 0.08
栻 NDEA (200 mg/kg) + CCl4 (3 mL/kg) 159.0 ± 5.8   172.0 ± 8.6**  9.82 ± 0.53*   5.71 ± 0.52**
栿 FIE (200 mg/kg) + NDEA + CCl4 154.0 ± 5.1   212.0 ± 9.8##  8.03 ± 0.67#   3.78 ± 0.47##
桇 FIE (400 mg/kg) + NDEA + CCl4 160.0 ± 4.7    238.0 ± 9.5###   7.51 ± 0.43##    3.15 ± 0.43###
桋 Silymarin (200 mg/kg) + NDEA + CCl4 155.0 ± 7.9    240.0 ± 7.2###   7.37 ± 0.38##    3.07 ± 0.35###
桍 FIE alone (400 mg/kg) 154.0 ± 4.2 241.0 ± 8.4 6.95 ± 0.35 2.88 ± 0.31
Values are expressed as mean ± SEM of 6 rats in each group. *P<0.01, **P<0.001 compared with respective control group I. #P<0.05, ##P<0.01 
and  ###P<0.001 compared with  group II (NDEA +CCl4).
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Table 2
Effect of FIE on the development of nodules in the liver of control and NDEA induced HCC in rats.
Groups Treatment Nodules incidence [n(%)] Total no of nodules Average no of nodules/nodules bearing liver
栺 Control 0(0.00)   0 0.0
栻 NDEA (200 mg/kg) + CCl4 (3 mL/kg)     6(100.00) 43 7.2
栿 FIE (200 mg/kg) + NDEA + CCl4   4(66.67) 27 6.8
桇 FIE (400 mg/kg) + NDEA + CCl4   2(33.33) 13 6.5
桋 Silymarin (200 mg/kg) + NDEA + CCl4   2(33.33)   9 4.5
桍 FIE alone (400 mg/kg) 0(0.00)   0 0.0
Values are expressed as mean of 6 rats in each group.
Table 3
Effect of FIE on the activities of marker enzymes in the serum of control and NDEA induced HCC in rats.
Groups Treatment AST (U/L) ALT (U/L) ALP (U/L) 毭-GT (U/L) TBL (mg/dL)
栺 Control  92.13 ± 11.06 38.81 ± 5.11  57.14 ± 5.77 29.56 ± 4.37 0.73 ± 0.09
栻 NDEA (200 mg/kg) + CCl4 (3 mL/kg) 353.12 ± 20.23*  203.57 ± 16.68*   142.65 ± 10.12*  133.42 ± 14.43*  2.14 ± 0.23*
栿 FIE (200 mg/kg)+ NDEA + CCl4  247.63 ± 16.47##   133.41 ± 12.22## 111.56 ± 8.17#  92.13 ± 9.82#  1.48 ± 0.16#
桇 FIE (400 mg/kg)+ NDEA + CCl4  129.18 ± 12.67##   68.81 ± 8.91##    84.76 ± 8.63##   49.48 ± 5.13##   0.96 ± 0.11##
桋 Silymarin (200 mg/kg) + NDEA + CCl4  114.36 ± 10.21##   54.17 ± 6.47##    68.54 ± 5.31##   38.22 ± 4.66##   0.87 ± 0.09##
桍 FIE alone (400 mg/kg)  86.21 ± 13.01 36.23 ± 7.46  54.43 ± 5.17   27.98 ± 4.13## 0.77 ± 0.06
Values are expressed as mean ± SEM of 6 rats in each group. *P<0.001 compared with respective control group 栺. #P<0.01, ##P<0.001 
compared with  group 栻 (NDEA +CCl4 ). 
treated group 桇 activity was less to standard silymarin-
treated group 桋 rats at the concentration used. The animals 
treated with FIE alone (400 mg/kg) showed no significant 
change in the body weight and relative liver weight when 
compared to control group 栺.
 
3.2.  Effect of FIE on the development of liver nodules
  Table 2 shows the total number of nodules, nodule 
incidence and average no of nodules per nodule bearing 
liver in the normal and experimental groups of animals. 
When rats were treated with NDEA (group 栻), 100% 
developed nodules in the liver were observed, whereas 
administration of FIE 200 mg/kg (group 栿) and 400 mg/kg
(group 桇) showed marked decrease in the number and 
multiplicity of the nodules as compared to group 栻 rats. 
The incidence of nodule growth was reduced to 66.67% in 
group 栿 and 33.33% in group 桇, respectively. The nodule 
incidence of FIE treated group 桇 was less to standard 
silymarin treated group 桋 rats. The occurrence of hepatic 
nodules was not observed in the normal group 栺 and FIE 
alone treated group 桍 animals.
 
3.3. Effect of FIE on liver injury and cancer markers
  The effect of FIE on liver injury is shown in Table 3, 
NDEA-treated group 栻 rats showed increased serum AST 
[(353.12 ± 20.23) U/L, P<0.001], ALT [(203.57 ± 16.68) U/L,
P<0.001], ALP [(142.65 ± 10.12) U/L, P<0.001], 毭GT [(133.42 
± 14.43) U/L, P<0.001] and TBL [(2.14 ± 0.23) mg/dL, P<0.001] 
compared to control group I rats [(92.13 ± 11.06) U/L,
(38.81 ± 5.11) U/L, (57.14 ± 5.77) U/L, (29.56 ± 4.37) U/L and
(0.73 ± 0.09 ) mg/dL], respectively. In contrast, the FIE-
cotreated groups 栿 and 桇 rats at 200 and 400 mg/kg 
significantly decreased AST [(247.63 ± 16.47) and (129.18 ± 
12.67) U/L, P<0.001], ALT [(133.41 ± 12.22) and (68.81 ± 8.91) U/L,
P<0.001], ALP [(111.56 ±8.17) and (84.76 ± 8.63) U/L, P<0.01 
and P<0.001], 毭GT [(92.13 ± 9.82) and (49.48 ± 5.13) U/L, 
P<0.01 and P<0.001] and TBL [(1.48 ± 0.16) and (0.96 ± 0.11) 
mg/dL, P<0.01 and P<0.001], respectively compared to 
group 栻 animals. Figure 1 and 2 depicted the levels of the 
tumor markers AFP and CEA. Their levels were found to be 
increased significantly (AFP, 47.23 ± 4.71 ng/mL; CEA, 6.81 
± 0.83 ng/mL, P<0.001) in NDEA-induced rats whereas they 
were significantly decreased [AFP, (32.73 ± 3.42) and (18.31 ± 
2.91) ng/mL, P<0.01 and P<0.001; CEA, (4.63 ± 0.61) and (2.39 
± 0.47) ng/mL, P<0.01 and P<0.001] on cotreatment with 200 
and 400 mg/kg of FIE.
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Figure 1. Effect of FIE on the levels of AFP in the serum of control 
and NDEA induced HCC in rats. 
*P<0.001 compared with respective control group 栺. 
#P<0.01 and 
##P<0.001 compared with group栻 (NDEA +CCl4).
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Figure 2. Effect of FIE on the levels of  CEA in the serum of control 
and NDEA induced HCC in rats. 
*P<0.001 compared with respective control group 栺. #P<0.05 and 
##P<0.001 compared with group 栻 (NDEA +CCl4).
3.4. Histopathological observations
  The histpathological examinations basically support the 
results obtained from serum enzyme and tumor marker 
assays. Figure 3A revealed the normal architecture (group I) 
and hepatic cells with granulated cytoplasm, small uniform 
nuclei and nucleolus. Group 栻 NDEA-treated rats showed 
loss of architecture and neoplastic cells arranged in lobules 
separated by fibrous septa with inflammatory collection 
and small bile duct proliferation. Neoplastic cells were 
larger than normal cells with granular cytoplasm and larger 
hyperchromatic nuclei and hyaline globules (arrow) that 
represent proteins produced by the tumor cells (Figure 3B). 
Architecture of liver sections of FIE cotreated (200 mg/kg)
group 栿 rats showed normal architecture with some 
hepatocytes and minimal inflammatory cell infiltration 
around the portal triads with few malignant hepatocytes. 
(Figure 3C), whereas FIE cotreated (400 mg/kg) group 桇
rats showed normal architecture with few preneoplastically 
transformed cells and hepatocytes maintaining near normal 
architecture which was almost comparable to the standard 
silymarin-cotreated group 桋 rats (Figure 3D). Administration 
of 50% ethanolic extract of F. indica (400 mg/kg) alone
exhibited normal architecture of hepatocytes with granulated 
cytoplasm (Figure 3E).
3.5.  Effect of FIE treatment alone
  Surprisingly, when FIE (400 mg/kg) was administered to 
the non-NDEA-treated rats, no significant changes were 
observed in any of the enzyme and non-enzyme activities 
assayed when compared to normal control group 栺 rats. 
At this dose level, there were no significant changes in the 
histological observations depicting the non-toxic nature of 
FIE (Figure 3F).
Figure 3. Histological study of liver tissue in control and experimental 
groups of rats. 
(A) Group 栺: Control animals revealed normal architecture. (B) 
Group 栻: NDEA + CCl4 induced carcinoma bearing animal showing 
neoplastic hepatocyte with inflammatory collection and loss of 
architecture. Neoplastic cells were larger than normal cells with larger 
hyperchromatic nuclei and hyaline globules (arrow) that represent 
proteins produced by the tumor cells. (C) Group 栿: Administration 
of 50% ethanolic extract of FIE (200 mg/kg) on HCC bearing animal 
hepatocyte showing minimal inflammatory cell with few malignant 
hepatocytes. (D) Group 桇: Administration of 50% ethanolic extract 
of FIE (400 mg/kg) on HCC bearing animals exhibited hepatocyte 
maintaining near normal architecture. (E) Group 桋: Administration 
of silymarin (200 mg/kg) on HCC bearing animals shows the structure 
close to proximity of normal hepatocytes. (F) Group 桍: Administration 
of 50% ethanolic extract of FIE (400 mg/kg) alone exhibited normal 
architecture of hepatocytes indicating the non-toxic nature of the 
extract.
 
 
4. Discussion
  Natural products have long been used to prevent and 
treat many diseases, including cancer and thus they are 
good candidates for the development of anti-cancer drugs. 
The large population use ayurvedic medicine worldwide. 
Different in vivo and in vitro screening models are available 
for anticancer activity. The present investigation showed 
that oral administration of FIE counteracts the activities 
of tumor marker enzymes and prevents the development 
of HCC that is usually induced by NDEA and CCl4 in 
experimental rats. On metabolic biotransformation of NDEA 
produces promutagenic products, O6-ethyldeoxyguanosine 
and O4 and O6-ethyldeoxythymidine in liver which are 
responsible for their carcinogenic effects[31-37]. It is well 
established that CCl4 induces hepatotoxicity by metabolic 
activation and therefore selectively causes toxicity in liver 
cells maintaining a semi-normal metabolic function. CCl4 
is bio-transformed by cytochrome P450 enzyme system in 
the endoplasmic reticulum to produce trichloromethyl free 
radicals. Trichloromethyl free radicals (CCl3•) then combine 
with cellular lipids and proteins in the presence of oxygen 
to form trichloromethyl peroxyl radical, which further attack 
lipids on the membrane of endoplasmic reticulum faster than 
trichloromethyl free radical. Thus, trichloromethyl peroxyl 
free radical leads to elicitation of lipid peroxidation and 
destruction of Ca2+ homeostasis, resulting in cell death[38].
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  The results of the present study seem to provide support for 
the chemopreventive effects of FIE against NDEA-induced 
hepatocarcinogenesis in rats. There is an appreciable 
reduction in body weight and increase in liver weight 
observed in HCC bearing group 栻 rats as compared to 
control group 栺 rats. Decreased appetite and food intake 
contribute to the weight loss which could be an indirect 
indication of the declining hepatic function, an increase in 
the liver weight of the animals, which could be attributed to 
the formation of nodules and tumors in the liver following 
carcinogen exposure. Sreepriya and Bali[9] have also reported 
marked loss of body weight and increase in liver weights. 
The steadily increase in body weight and decrease in liver 
weight after FIE treatment (groups 栿 and 桇) indicate that, 
increased appetite and reduced tumor incidence shows its 
anticancer effectiveness. Administration of NDEA is reported 
to produce neoplastic nodules in experimental animals[9]. 
Group 栻 rats given NDEA showed an incidence of 100% in 
the presence of nodules. Administration of FIE was able to 
reduce the percentage incidence of nodules as compared 
to group 栻. The effect of FIE to prevent the multiplicity 
of neoplastic nodules gives substantial support to the 
chemopreventive effects of plant extract. Hepatic damage 
caused by NDEA and CCl4 generally reflects instability of 
liver cell metabolism which leads to distinctive changes in 
the serum enzyme activities[39]. Serum transaminases (AST 
and ALT), ALP, TBL and 毭-GT are representative of liver 
function and their increased levels are sensitive indicators 
of hepatic injury[4]. Elevated activities of serum AST and ALT 
in NDEA and CCl4 treated rats may be due to NDEA induced 
hepatic damage and subsequent leakage of these enzymes 
from the neoplastic cell into circulation[40]. In accordance 
with the above report we also observed an increase in liver 
marker enzyme as AST and ALT in NDEA and CCl4 treated 
group 栻 when compared to respective control group 栺 rats. 
Similarly, increase in ALP reflects pathological alteration 
in biliary flow and discharge of TBL reflects a non-
specific alteration in the plasma membrane integrity and/
or permeability[4]. 毭-GT is an enzyme embedded in the 
hepatocyte plasma membrane, mainly in the canalicular 
domain and its liberation into serum indicates damage of the 
cells and thus injury to liver[5]. It is important to point out 
that serum 毭-GT activity is considered to be one of the best 
indicators of liver damage[41]. In the present investigation, 
cotreatment with FIE significantly lowered the enhanced 
level of activities of these enzymes. It is suggested that FIE 
aids in parenchymal cell regeneration in liver and thereby 
protects membrane integrity by decreased enzyme leakage 
against carcinogenic effect of NDEA. 
  AFP is widely used as tumor marker for diagnosis of HCC, 
which is a unique immunomodulatory glycoprotein (65 kDa) 
normally made by the immature liver cells in the fetus[29]. 
Its detection during monitoring of HCC treatment is well 
accepted in patients with increased AFP levels prior to 
therapy, and is recommended by the European Association 
for the Study of the Liver. It has long been recognized 
that exposure of rats to certain carcinogens like NDEA 
increases the circulating AFP levels. This corroborates the 
results showing significant rise in levels of AFP obtained 
in NDEA-induced rats[5] and AFP levels were found to be 
significantly reduced in FIE cotreated (groups 栿 and 桇)
rats. CEA, a member of the immunoglobulin supergene 
family, is a 180-200 kDa heavily glycosylated protein. 
Frequently it is detected in a high concentration in the 
serum of individuals with malignancy in the liver[30,42]. 
In this study, an increase in serum CEA levels following 
NDEA treatment was presumably associated with production 
rates of tumor, its location, stage, size, differentiation and 
vascularity. The significant reductions in the levels of CEA 
in FIE cotreated groups 栿 and 桇 rats were presumably 
due to decreased production rates of tumors. To verify 
the anticancer activity of FIE, histopathological studies 
were carried out. In this investigation, marked changes 
were observed in the architecture of liver of cancer 
bearing animals. These indicate the presence of neoplastic 
conditions following NDEA and CCl4 administration. In FIE 
treated animals, the NDEA and CCl4 damage was recovered 
due to anticancer potency of F. indica extract. From 
our study, it is concluded that the oral administration of
F. indica would exert regression of hepatocarcinogenesis 
induced by NDEA and CCl4 may be due to restoring the 
activities of entire liver cancer marker enzymes and 
diminution in tumor incidence. Further investigations are 
required to understand the detailed mechanism of action 
which may lead to identification of potent molecules from F. 
indica against NDEA and CCl4-induced HCC. 
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